2023
DOI: 10.3390/jcm12206527
|View full text |Cite
|
Sign up to set email alerts
|

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Anish J. Jain,
Brian D. Badgwell

Abstract: Gastric cancer (GCa) is an aggressive malignancy, representing the third leading cause of cancer mortality worldwide. The poor prognosis of GCa can be associated with the prevalence of peritoneal metastasis (PM). Current international and national GCa treatment guidelines only recommend palliative treatment options for patients with PM. Since the 1980s there have been multiple single arm trials, randomized controlled trials, and metanalysis investigating the use of cytoreductive surgery (CRS) and hyperthermic … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 65 publications
0
2
0
Order By: Relevance
“…This technique can classify patients with GC at diagnosis, indicating a poorer prognosis for those with positive cytology in PLF. Therefore, it is advisable to implement preemptive interventional measures such as hyperthermic intraperitoneal chemotherapy (HIPEC) for this high-risk population ( Lei et al, 2020 ; Jain & Badgwell, 2023 ; Buckarma et al, 2024 ; Xu & Wang, 2023 ). Our follow-up research plan is to treat FCCs-positive patients with HIPEC (using nab-paclitaxel) and compare their outcomes to those of FCCs-positive patients not receiving HIPEC and FCCs-negative patients, to explore the preventive effect of HIPEC on patients with OPM.…”
Section: Discussionmentioning
confidence: 99%
“…This technique can classify patients with GC at diagnosis, indicating a poorer prognosis for those with positive cytology in PLF. Therefore, it is advisable to implement preemptive interventional measures such as hyperthermic intraperitoneal chemotherapy (HIPEC) for this high-risk population ( Lei et al, 2020 ; Jain & Badgwell, 2023 ; Buckarma et al, 2024 ; Xu & Wang, 2023 ). Our follow-up research plan is to treat FCCs-positive patients with HIPEC (using nab-paclitaxel) and compare their outcomes to those of FCCs-positive patients not receiving HIPEC and FCCs-negative patients, to explore the preventive effect of HIPEC on patients with OPM.…”
Section: Discussionmentioning
confidence: 99%
“…2,3 However, the criteria used to identify such cases have not been prospectively validated and are largely based on the attitude and expertise of the single multidisciplinary teams. 4…”
Section: To the Editormentioning
confidence: 99%